Is Incannex Healthcare Inc. (IXHL) Halal?

NASDAQ Healthcare Australia $45M
? INSUFFICIENT DATA
Confidence: 8/100
Incannex Healthcare Inc. (IXHL) has insufficient data for a complete Shariah compliance screening. This may be due to missing financial statements or incomplete market data.

Shariah Screening — 5 Standards

Based on financial data from June 2025

Standard Debt Ratio Cash Ratio Receivables Income Status
AAOIFI N/A N/A N/A N/A ? INSUFFICIENT DATA
DJIM N/A N/A N/A N/A ? INSUFFICIENT DATA
MSCI N/A N/A N/A N/A ? INSUFFICIENT DATA
S&P N/A N/A N/A N/A ? INSUFFICIENT DATA
FTSE N/A N/A N/A N/A ? INSUFFICIENT DATA

Financial Highlights

EPS
$-22.20
P/B Ratio
0.5
EV/EBITDA
1.2
EV: -$30M
Beta
2.7
High volatility
Current Ratio
48.3

Profitability

Gross Margin 0.0%
Operating Margin 0.0%
Net Margin 0.0%
Return on Equity (ROE) -130.4%
Return on Assets (ROA) -37.0%

Cash Flow & Balance Sheet

Operating Cash Flow-$16M
Free Cash Flow-$16M
Debt-to-Equity0.2
Current Ratio48.3

Price & Trading

Last Close$3.41
50-Day MA$6.63
200-Day MA$11.50
Avg Volume420K
Beta2.7
52-Week Range
$2.40
$49.80

About Incannex Healthcare Inc. (IXHL)

CEO
Mr. Joel Bradley Latham
Employees
12
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
Australia
Exchange
NASDAQ
Market Cap
$45M
Currency
USD

Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder. It is also developing IHL-675A, an oral fixed dose combination drug containing synthetic cannabidiol and hydroxychloroquine sulphate to treat rheumatoid arthritis, as well as lung inflammation, acute respiratory disease, chronic obstructive pulmonary disease, asthma, bronchitis, inflammatory bowel disease, colitis, and Crohn's disease. Incannex Healthcare Inc. is headquartered in Sydney, Australia.

Related Halal Stocks in Healthcare

Frequently Asked Questions

Is Incannex Healthcare Inc. (IXHL) halal to invest in?

Based on our screening using AAOIFI Standard 21 (the strictest methodology), Incannex Healthcare Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.

What is Incannex Healthcare Inc.'s debt ratio?

Incannex Healthcare Inc.'s debt ratio is not available under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%.

What are Incannex Healthcare Inc.'s key financial metrics?

Incannex Healthcare Inc. has a market capitalization of $45M. Return on equity stands at -130.4%.

How often is the screening data updated?

Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.

Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.